OS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 100,000 Shares of Stock

OS Therapies Inc (NYSE:OSTX) major shareholder Shalom Auerbach sold 100,000 shares of OS Therapies stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $2.84, for a total transaction of $284,000.00. Following the completion of the transaction, the insider now directly owns 2,431,211 shares of the company’s stock, valued at $6,904,639.24. This trade represents a 3.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shalom Auerbach also recently made the following trade(s):

• On Wednesday, January 15th, Shalom Auerbach sold 16,720 shares of OS Therapies stock. The stock was sold at an average price of $6.74, for a total transaction of $112,692.80.

OS Therapies Trading Down 11.7 %

Shares of OSTX stock opened at $1.97 on Wednesday. The company has a 50 day moving average price of $3.40 and a 200-day moving average price of $3.16. OS Therapies Inc has a 52 week low of $1.58 and a 52 week high of $7.00.

Institutional Trading of OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC lifted its stake in OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 110,044 shares of the company’s stock after acquiring an additional 60,044 shares during the quarter. CM Management LLC owned 0.51% of OS Therapies worth $471,000 as of its most recent filing with the Securities & Exchange Commission.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on OSTX shares. Maxim Group lifted their target price on shares of OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th. D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 target price on shares of OS Therapies in a report on Thursday, January 30th.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.